Crenessity CAH denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for crenessity cah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Crenessity for CAH as Experimental — and Why You Can Appeal

Blue Cross Blue Shield plans sometimes apply an "experimental or investigational" exclusion to newly approved medications, even after FDA approval, if the plan's medical policy has not yet been updated to reflect the approval or if the plan's review process classifies the drug as lacking sufficient "proven" evidence under its internal criteria. For Crenessity (tildacerfont), approved by the FDA for congenital adrenal hyperplasia, this type of denial is particularly contestable.

The FDA approval means the agency has determined the drug is safe and effective for its labeled indication based on review of clinical trial data. A plan's internal "experimental" designation that overrides an FDA approval is a strong candidate for reversal on appeal, especially through independent external review.

## Federal Appeal Rights

• ACA §2719 external review: This is a priority route for experimental-designation denials. An independent external reviewer — a physician with relevant specialty expertise — evaluates whether the denial meets the plan's stated criteria using current clinical evidence. The standard window to request external review is approximately four months from the final internal denial; confirm your exact deadline on the denial letter. Expedited review is available for urgent situations.
• ERISA §503: If you have an employer-sponsored plan, you are entitled to a written explanation of the specific evidence review standard the plan applied and which studies or guidelines it relied upon to classify Crenessity as experimental.
• State insurance laws: Many states require that experimental designations be based on recognized clinical evidence standards, and several states give patients explicit rights to coverage when a drug is FDA-approved for the diagnosed condition.

## Concrete Appeal Steps

1. Request BCBS's medical policy for Crenessity and its definition of "experimental or investigational." Ask for the specific evidence criteria the plan applies. 2. Obtain your prescriber's letter citing the FDA approval of Crenessity, the relevant professional society guidelines (such as the applicable Endocrine Society guideline for CAH management), and the clinical evidence supporting its use — without citing specific trial statistics, focus on the fact of FDA approval and guideline recognition. 3. Gather diagnosis and treatment records: CAH diagnosis documentation, endocrinology notes, and records showing disease status and current treatment history. 4. File the internal appeal within the plan's stated window. If denied again, immediately request external review.

## Criteria-Mapping Structure

| Experimental-Designation Criterion | Your Supporting Documentation | |---|---| | Drug lacks FDA approval for indicated use | FDA approval letter / prescribing label confirming indication | | Not recognized in clinical practice guidelines | Prescriber letter referencing applicable Endocrine Society guideline | | Insufficient clinical evidence | Prescriber letter summarizing evidentiary basis for approval |

Obtain the exact current version of BCBS's experimental-drug policy before submitting so your appeal directly addresses each criterion used.